Mitsubishi Tanabe Pharma Corporation (4508):企業の財務及び戦略的SWOT分析

【英語タイトル】Mitsubishi Tanabe Pharma Corporation (4508) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(GDPH31436FSA)・商品コード:GDPH31436FSA
・発行会社(調査会社):GlobalData
・発行日:2016年1月25日
・ページ数:59
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:日本
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD125 ⇒換算¥14,125見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD375 ⇒換算¥42,375見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Mitsubishi Tanabe Pharma Corporation (4508) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe) is a pharmaceutical company that identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes and kidney diseases, central nervous system (CNS) diseases and others, and it also develops vaccines. It supplies pharmaceutical products to wholesalers, hospitals, clinics, and drugstores. It also offers fine chemicals, information services, real-estate leasing and advertising, among others. The company operates through subsidiaries in Asia, Europe and North America.

Mitsubishi Tanabe Pharma Corporation Key Recent Developments

Dec 12,2015 Japanese company loses patent bid for diabetes drug
Nov 30,2015 Mitsubishi Tanabe Pharma Formulates Medium-Term Management Plan 16-20: Open Up the Future
Oct 30,2015 Mitsubishi Tanabe Pharma Reports Net Sales Of JPY201.7 Billion For The Six Months Ended September 30, 2015
Oct 01,2015 Torrent wins patent battle against Novartis’ $2.5 billion drug Gilenya in US

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 – About the Company 6
Mitsubishi Tanabe Pharma Corporation – Key Facts 6
Mitsubishi Tanabe Pharma Corporation – Key Employees 7
Mitsubishi Tanabe Pharma Corporation – Major Products and Services 8
Mitsubishi Tanabe Pharma Corporation – Pharmaceutical Pipeline Products Data 10
Mitsubishi Tanabe Pharma Corporation, Pipeline Products by Therapy Area 10
Mitsubishi Tanabe Pharma Corporation, Pipeline Products by Development Phase 11
Mitsubishi Tanabe Pharma Corporation – History 14
Mitsubishi Tanabe Pharma Corporation – Company Statement 20
Mitsubishi Tanabe Pharma Corporation – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Section 2 – Company Analysis 25
Mitsubishi Tanabe Pharma Corporation – Business Description 25
Mitsubishi Tanabe Pharma Corporation – Corporate Strategy 27
Mitsubishi Tanabe Pharma Corporation – SWOT Analysis 28
SWOT Analysis – Overview 28
Mitsubishi Tanabe Pharma Corporation – Strengths 28
Strength – Integrated Network of Products 28
Strength – Research and Development 28
Strength – Growth in Pharmaceutical Segment 28
Mitsubishi Tanabe Pharma Corporation – Weaknesses 29
Weakness – Higher Cost Structure 29
Mitsubishi Tanabe Pharma Corporation – Opportunities 30
Opportunity – Market Potential – Central Nervous System 30
Opportunity – Business Initiatives 30
Opportunity – Product Pipeline 30
Mitsubishi Tanabe Pharma Corporation – Threats 31
Threat – Competitive Environment 31
Threat – Government Regulations 31
Threat – Uncertain R&D Outcomes 31
Mitsubishi Tanabe Pharma Corporation – Key Competitors 32
Section 3 – Company Financial Ratios 33
Financial Ratios – Capital Market Ratios 33
Financial Ratios – Annual Ratios 34
Performance Chart 36
Financial Performance 36
Financial Ratios – Interim Ratios 37
Financial Ratios – Ratio Charts 38
Section 4 – Company’s Lifesciences Financial Deals and Alliances 39
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 39
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 40
Mitsubishi Tanabe Pharma Corporation, Recent Deals Summary 41
Section 5 – Company’s Recent Developments 43
Nov 30, 2015: Mitsubishi Tanabe Pharma Formulates Medium-Term Management Plan 16-20: Open Up the Future 43
Oct 30, 2015: Mitsubishi Tanabe Pharma Reports Net Sales Of JPY201.7 Billion For The Six Months Ended September 30, 2015 45
Jul 31, 2015: Mitsubishi Tanabe Pharma Reports Net Sales Of JPY98.5 Billion In Q1 Fiscal 2016 46
Jul 27, 2015: Mitsubishi Tanabe Pharma announces organizational restructuring 47
May 08, 2015: Mitsubishi Tanabe Pharma Reports Net Sales Of JPY415.1 Billion In Fiscal 2015 49
Feb 25, 2015: Reorganization of research bases in Japan 50
Feb 25, 2015: Medicago Develops Alternative Production Process for Ebola Antibodies Contract concluded with U.S. government 51
Feb 06, 2015: Completion of Construction of the New Head Office Building 52
Feb 02, 2015: Mitsubishi Tanabe Pharma Reports Net Sales Of JPY319.8 Billion For The Nine Months Ended December 31, 2014 53
Jan 29, 2015: Increasing Production Capacity to Meet Growing Asian Pharmaceutical Markets – Completion of New Manufacturing Facility 54
Section 6 – Appendix 55
Methodology 55
Ratio Definitions 55
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Mitsubishi Tanabe Pharma Corporation, Key Facts 6
Mitsubishi Tanabe Pharma Corporation, Key Employees 7
Mitsubishi Tanabe Pharma Corporation, Major Products and Services 8
Mitsubishi Tanabe Pharma Corporation, Number of Pipeline Products by Therapy Area 10
Mitsubishi Tanabe Pharma Corporation, Number of Pipeline Products by Development Stage 11
Mitsubishi Tanabe Pharma Corporation, Pipeline Products By Therapy Area and Development Phase 12
Mitsubishi Tanabe Pharma Corporation, History 14
Mitsubishi Tanabe Pharma Corporation, Other Locations 21
Mitsubishi Tanabe Pharma Corporation, Subsidiaries 21
Mitsubishi Tanabe Pharma Corporation, Key Competitors 32
Mitsubishi Tanabe Pharma Corporation, Ratios based on current share price 33
Mitsubishi Tanabe Pharma Corporation, Annual Ratios 34
Mitsubishi Tanabe Pharma Corporation, Interim Ratios 37
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 39
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 40
Mitsubishi Tanabe Pharma Corporation, Recent Deals Summary 41
Currency Codes 55
Capital Market Ratios 55
Equity Ratios 56
Profitability Ratios 56
Cost Ratios 57
Liquidity Ratios 57
Leverage Ratios 58
Efficiency Ratios 58

List of Figures
Mitsubishi Tanabe Pharma Corporation, Pipeline Products by Therapy Area 10
Mitsubishi Tanabe Pharma Corporation, Pipeline Products by Development Phase 11
Mitsubishi Tanabe Pharma Corporation, Performance Chart (2011 - 2015) 36
Mitsubishi Tanabe Pharma Corporation, Ratio Charts 38
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 39
Mitsubishi Tanabe Pharma Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 40

★調査レポート[Mitsubishi Tanabe Pharma Corporation (4508):企業の財務及び戦略的SWOT分析] (コード:GDPH31436FSA)販売に関する免責事項を必ずご確認ください。
★調査レポート[Mitsubishi Tanabe Pharma Corporation (4508):企業の財務及び戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆